Total Payments
$3,642
2024 Payments
$486.43
Companies
19
Transactions
102
Medicare Patients
17,254
Medicare Billing
$16.0M
Payment Breakdown by Category
Food & Beverage$2,299 (63.1%)
Travel$975.99 (26.8%)
Other$367.50 (10.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,299 | 97 | 63.1% |
| Travel and Lodging | $975.99 | 1 | 26.8% |
| Entertainment | $332.97 | 1 | 9.1% |
| Honoraria | $34.53 | 3 | 0.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $1,336 | 3 | $0 (2019) |
| Genentech USA, Inc. | $377.17 | 18 | $0 (2024) |
| Allergan, Inc. | $373.62 | 17 | $0 (2021) |
| Marco Ophthalmic, Inc. | $332.97 | 1 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $272.26 | 16 | $0 (2024) |
| ABBVIE INC. | $179.60 | 10 | $0 (2024) |
| Alimera Sciences, Inc. | $148.57 | 8 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $132.49 | 6 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $68.79 | 3 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $62.08 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $486.43 | 25 | Regeneron Healthcare Solutions, Inc. ($140.61) |
| 2023 | $246.41 | 12 | Coherus Biosciences Inc. ($45.50) |
| 2022 | $172.90 | 9 | ABBVIE INC. ($39.96) |
| 2021 | $238.34 | 8 | Allergan, Inc. ($220.74) |
| 2020 | $53.72 | 4 | Allergan, Inc. ($39.45) |
| 2019 | $1,484 | 12 | Genentech, Inc. ($1,328) |
| 2018 | $352.74 | 16 | Genentech USA, Inc. ($113.86) |
| 2017 | $607.24 | 16 | Marco Ophthalmic, Inc. ($332.97) |
All Payment Transactions
102 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: EYE CARE | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.06 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/05/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Ophthalmology | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $0.93 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/01/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: EYE CARE | ||||||
| 07/25/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: Immunology and Ophthalmology | ||||||
| 07/11/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: EYE CARE | ||||||
| 06/27/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: OPHTHALMOLOGY | ||||||
| 06/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/16/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Ophthalmology | ||||||
| 05/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Ophthalmology | ||||||
| 04/22/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $28.75 | General |
| Category: Ophthalmology | ||||||
| 04/15/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $17.30 | General |
| Category: EYE CARE | ||||||
| 04/03/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: EYE CARE | ||||||
| 03/28/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/26/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $23.88 | General |
| Category: Ophthalmology | ||||||
| 03/12/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Ophthalmology | ||||||
| 03/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: OPHTHALMOLOGY | ||||||
| 03/04/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $13.53 | General |
| Category: EYE CARE | ||||||
| 02/23/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Ophthalmology | ||||||
| 02/15/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 02/07/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 22 | 4,262 | 26,799 | $13.4M | $4.0M |
| 2022 | 21 | 4,215 | 18,209 | $12.5M | $3.9M |
| 2021 | 19 | 4,515 | 17,908 | $12.6M | $4.0M |
| 2020 | 22 | 4,262 | 18,500 | $12.7M | $4.1M |
Total Patients
17,254
Total Services
81,416
Medicare Billing
$16.0M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 340 | 3,901 | $7.2M | $2.7M | 37.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 42 | 11,940 | $1.4M | $347,108 | 24.8% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 72 | 1,901 | $1.5M | $340,387 | 22.3% |
| 67028 | Injection of drug into eye | Office | 2023 | 526 | 2,516 | $1.8M | $221,143 | 12.6% |
| 92134 | Imaging of retina | Office | 2023 | 1,010 | 3,331 | $333,100 | $92,562 | 27.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 668 | 929 | $209,025 | $77,449 | 37.1% |
| J3590 | Unclassified biologics | Office | 2023 | 109 | 348 | $253,300 | $68,330 | 27.0% |
| J3490 | Unclassified drugs | Office | 2023 | 15 | 34 | $220,250 | $61,129 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 250 | 319 | $63,800 | $27,732 | 43.5% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 16 | 210 | $90,090 | $25,697 | 28.5% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 239 | 249 | $49,800 | $24,877 | 50.0% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 162 | 162 | $32,400 | $16,578 | 51.2% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 18 | 18 | $54,000 | $15,586 | 28.9% |
| 92250 | Photography of the retina | Office | 2023 | 462 | 550 | $68,750 | $13,577 | 19.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 79 | 79 | $19,750 | $8,544 | 43.3% |
| 76510 | 1d and 2d ultrasound scan of eye tissue and structures | Office | 2023 | 93 | 132 | $40,500 | $6,383 | 15.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 56 | 56 | $8,960 | $4,217 | 47.1% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 11 | 14 | $14,000 | $3,624 | 25.9% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 53 | 60 | $13,510 | $1,896 | 14.0% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 15 | 16 | $2,400 | $1,040 | 43.3% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 13 | 18 | $4,500 | $1,002 | 22.3% |
| 76513 | Ultrasound scan of eye using water bath method | Office | 2023 | 13 | 16 | $2,880 | $898.30 | 31.2% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 313 | 3,474 | $6.4M | $2.5M | 38.5% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 144 | 3,291 | $2.6M | $714,440 | 27.1% |
| 67028 | Injection of drug into eye | Office | 2022 | 513 | 2,477 | $1.7M | $218,006 | 12.6% |
About Dr. Gregory Fox, M.D
Dr. Gregory Fox, M.D is a Ophthalmology healthcare provider based in Lenexa, Kansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1225070717.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Fox, M.D has received a total of $3,642 in payments from pharmaceutical and medical device companies, with $486.43 received in 2024. These payments were reported across 102 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($2,299).
As a Medicare-enrolled provider, Fox has provided services to 17,254 Medicare beneficiaries, totaling 81,416 services with total Medicare billing of $16.0M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Retina Specialist
- Location Lenexa, KS
- Active Since 06/11/2006
- Last Updated 08/26/2022
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1225070717
Products in Payments
- Non-Covered Product (Drug) $1,328
- OZURDEX (Drug) $553.22
- OPD-III (Device) $332.97
- Lucentis (Biological) $315.87
- EYLEA (Biological) $160.02
- Syfovre (Drug) $89.04
- XIPERE (Drug) $68.79
- VISUDYNE (Drug) $62.08
- Spectralis (Device) $59.97
- EYLEA AFLIBERCEPT INJECTION (Biological) $57.70
- EYLEA HD (Biological) $54.54
- PURIFIED CORTROPHIN GEL (Drug) $52.16
- Iluvien (Biological) $49.54
- Vabysmo (Drug) $46.75
- Cimerli (Biological) $45.50
- ILUVIEN (Drug) $42.45
- Izervay (Drug) $41.31
- ForeseeHome (Device) $40.92
- Constellation (Device) $36.70
- Monaco (Device) $28.44
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Lenexa
Dr. Michael Ellis
Ophthalmology — Payments: $37,104
Ophthalmology $37,104
Dr. Daniel Feiler, M.d, M.D
Ophthalmology — Payments: $30,509
Ophthalmology $30,509
Dr. Ivan Batlle, Md, MD
Ophthalmology — Payments: $9,083
Ophthalmology $9,083
Dr. David Dyer, M.d, M.D
Ophthalmology — Payments: $8,164
Ophthalmology $8,164
Dr. Neeti Alapati, Md, MD
Ophthalmology — Payments: $3,894
Ophthalmology $3,894
Dr. Steven Cohen, M.d, M.D
Ophthalmology — Payments: $3,166
Ophthalmology $3,166